Gossamer bio announces inducement grant under nasdaq listing rule 5635(c)(4)

San diego--(business wire)---- $goss--gossamer bio, inc. (nasdaq: goss), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (pah) and pulmonary hypertension associated with interstitial lung disease (ph-ild), today announced that the compensation committee of gossamer's board of directors approved the grant, effective may 5, 2025, to three non-executive employees of non-qualified stock optio.
GOSS Ratings Summary
GOSS Quant Ranking